Cormark reissued their buy rating on shares of Zymeworks Inc (NASDAQ:ZYME) in a report released on Saturday morning.

Several other research firms also recently weighed in on ZYME. Zacks Investment Research downgraded Zymeworks from a hold rating to a sell rating in a research report on Saturday, August 12th. Barclays PLC restated an underweight rating and issued a $8.00 price target on shares of Zymeworks in a report on Thursday, September 7th. Finally, Scotiabank cut shares of Zymeworks from an overweight rating to an underweight rating in a report on Thursday, September 7th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $16.00.

Zymeworks (NASDAQ:ZYME) opened at 8.44 on Friday. The company’s market capitalization is $213.86 million. The firm has a 50-day moving average of $7.89 and a 200 day moving average of $9.06. Zymeworks has a one year low of $6.25 and a one year high of $14.25.

WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at

Several institutional investors have recently bought and sold shares of the company. Barometer Capital Management Inc. purchased a new stake in shares of Zymeworks in the second quarter valued at approximately $484,000. Franklin Resources Inc. purchased a new position in Zymeworks during the 2nd quarter worth $6,878,000. OxFORD Asset Management LLP purchased a new position in Zymeworks during the 2nd quarter worth $154,000. Finally, Sentry Investments Corp. purchased a new position in Zymeworks during the 2nd quarter worth $206,000.

About Zymeworks

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Analyst Recommendations for Zymeworks (NASDAQ:ZYME)

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.